阿德福韦酯分别联合恩替卡韦或替诺福韦治疗rtA181V/T单位点突变的慢性乙型肝炎患者疗效初步研究*

doi:10.3969/j.issn.1672-5069.2022.03.007

摘要/Abstract

摘要： 目的研究应用阿德福韦酯(ADV)分别联合替诺福韦(TDF)或恩替卡韦(ETV)治疗rtA181V/T单位点突变的慢性乙型肝炎(CHB)患者的疗效。方法 2017年1月～2020年1月我院感染病科收治的50例rtA181V/T单位点突变的CHB患者被随机分为ADV联合TDF治疗25例和ADV联合ETV治疗25例,治疗观察48 w。采用实时荧光定量PCR法检测血清HBV DNA载量,使用全自动生化分析仪检测血生化指标,包括β2-微球蛋白(β2-MG)和视黄醇结合蛋白(RBP),并计算估算的肾小球滤过率(eGFR)和内生肌酐清除率(Crcl),采用ELISA法检测血清HBsAg和HBeAg,使用流式细胞仪检测外周血T淋巴细胞亚群。结果在治疗24 w和48 w,ADV联合TDF治疗组血清HBV DNA转阴率分别为100.0%和100.0%,与ADV联合ETV治疗组(分别为96.0%和96.0%)比,无显著性差异(P>0.05);血清AST水平分别为(49.2±5.5)U/L和(30.4±4.0)U/L,显著低于ADV联合ETV治疗组【分别为(55.3±7.0) U/L和(43.2±6.8) U/L,P<0.05】,血清ALT水平分别为(40.3±6.1) U/L和(39.1±4.3) U/L,显著低于ADV联合ETV治疗组【分别为(65.1±7.5)U/L和(45.3±6.1)U/L,P<0.05】,血清HBV DNA水平分别为(0.8±0.2)lg IU/mL和(2.0±0.4)lg IU/mL,显著低于ADV联合ETV治疗组【分别为 (2.9±0.3)lg IU/mL和(1.2±0.2) lg IU/mL,P<0.05】;外周血CD4⁺细胞百分比分别为(45.2±3.6)%和(48.3±4.2)%,CD4⁺/CD8⁺细胞比值分别为(1.4±0.2)和(1.8±0.1),显著高于ADV联合ETV治疗组【分别为(42.4±3.1)%和(45.0±3.2)%,和(1.2±0.1)和(1.5±0.1),P<0.05】;在观察期内,两组肾功能指标无显著性变化。结论应用ADV联合TDF治疗rtA181V/T单位点突变的CHB患者近期效果较好,能够快速抑制病毒复制,稳定肝功能,对肾功能影响较小。

关键词: 慢性乙型肝炎, rtA181V/T突变, 替诺福韦, 恩替卡韦, 阿德福韦酯, 挽救治疗

Abstract: Objective The aim of this study was to investigate the short-term efficacy of adefovir dipivoxil (ADV) and entecavir (ETV) or tenofovir (TDF) combination rescued therapy in patients with chronic hepatitis B and rtA181V/T mutation. Methods Fifty patients with CHB and rtA181V/T mutation were admitted to the Department of Infectious Diseases in our hospital between January 2017 and January 2020, and were divided randomly into two groups, receiving ADV and TDF or ADV and ETV treatment, with 25 cases in each. Serum HBV DNA loads was assayed by real-time fluorescent quantitative PCR. Serum β2-microglobulin (β2-MG), retinol-binding protein (RBP) and serum creatinine (sCr) were detected, and creatinine clearance (Crcl) and estimaated glomerular filtration rate (eGFR) were calculated. Peripheral blood T lymphocytes were performed by flow cytometry. Results At the end of 24-week and 48-week, serum HBV DNA negative rate in patients receiving ADV and TDF combination treatment were 100.0% and 100.0%, not significantly different compared to 96.0% and 96.0%, respectively, in ADV and ETV combination-treated patients (P>0.05); serum AST levels were (49.2±5.5)U/L and (30.4±4.0)U/L, significantly lower than [(55.3±7.0) U/L and (43.2±6.8) U/L, respectively, P<0.05], serum ALT levels were (40.3±6.1) U/L and (39.1±4.3) U/L, significantly lower than [(65.1±7.5)U/L and (45.3±6.1)U/L,P<0.05], and serum HBV DNA loads were (0.8±0.2)lg IU/mL and (2.0±0.4)lg IU/mL, significantly lower than [(2.9±0.3)lg IU/mL and (1.2±0.2) lg IU/mL, respectively, P<0.05] in ADV and ETV combination-treated patients; the percentages of peripheral blood CD4⁺ cells were(45.2±3.6)% and (48.3±4.2)%, and the ratios of CD4⁺/CD8⁺ cells were (1.4±0.2) and (1.8±0.1), significantly higher than [(42.4±3.1)% and (45.0±3.2)%, and (1.2±0.1)and (1.5±0.1), respectively, P<0.05] in ADV and ETV combination-treated patients; there was no significant changes of renal function tests in the two groups. Conclusion The short-term efficacy of ADV and TDF combination therapy in patients with CHB and rtA181V/T mutation is good, with the rapid inhibition of viral replication and stable liver function tests without side effects.

Key words: Hepatitis B, rtA181V/T mutation, Tenofovir, Entecavir, Adefovir dipivoxil, Rescued therapy

邹东花, 秘建威, 李玉苓, 赵森. 阿德福韦酯分别联合恩替卡韦或替诺福韦治疗rtA181V/T单位点突变的慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 331-334.

Zou Donghua, Mi Jianwei, Li Yuling, et al. Rescued therapy of patients with chronic hepatitis B and rtA181V/T mutation by adefovir dipivoxiland entecavir or tenofovir combination[J]. Journal of Practical Hepatology, 2022, 25(3): 331-334.

参考文献

[1] Edward J G, Hyung J K, Kumar V,et al. Safety, pharmacokinetics, and pharmacodynamics of the oral TLR8 agonist selgantolimod in chronic hepatitis B. Hepatology, 2021,74(4):1737-1749.
[2] Pan HY, Pan HY, Song WY, et al. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.J Viral Hepat,2017, 24(Suppl 1):29-35.
[3] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance. Hepatology, 2018,67(4):1560-1599.
[4] Grassi A, Ballardini G. Hepatitis C in injection drug users:It is time to treat. World J Gastroenterol, 2017,23(20):3569-3571.
[5] 庄辉,翁心华.核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理.中华肝脏病杂志,2013,21(1):15-22.
[6] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2010年版).实用肝脏病杂志,2011,14(2):81-89.
[7] Lok AS, McMahon BJ. Chronic hepatitis B:update 2009.Hepatology,2009,50(3):661-662.
[8] Yeh CT, Chien RN, Chu CM,et al. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology, 2000, 31(6):1318-1326.
[9] Zhao L, Li X, Cheng Y,et al. Hepatitis B virus rtA181T/sW172 non-stop mutation may increase resistance fold to adefovir-and entecavir-resistant mutants compared to rtA181T/sW172* mutation. Antiviral Res,2018, 154:26-34.
[10] 姬粉芝,王磊,杨保华,等. rtA181位点突变乙型肝炎病毒感染患者的临床特点及个体化再治疗效果.中华肝脏病杂志,2012,20(4):280-284.
[11] Lee HW, Park JY, Lee JW, et al. Long-term efficacy of tenofovir disoproxil fumarate monotherapy for multidrug-resistant chronic HBV infection.Clin Gastroenterol Hepatol,2019, 17(7):1348-1355.
[12] Woo HY, Park JY, Bae SH, et al. Lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.Clin Mol Hepatol, 2020, 26(3):352-363.
[13] Choe WH, Kim K, Lee SY, et al. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations.World J Gastroenterol, 2019,25(33):4985-4998.
[14] 郑书琴, 陆建春, 史建国,等. 替诺福韦艾拉酚胺用于拉米夫定耐药与肾功能不全患者的挽救治疗1例. 中华传染病杂志, 2019, 37(7):435-436.
[15] Boni C, Vecchi A, Rossi M, et al. TLR7 agonist increases responses of hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis b treated with nucleos(t)ide analogues. Gastroenterology, 2018, 154(6):1764-1777.
[16] 邓浩辉, 许敏, 楼燕,等. 替比夫定单药或联合阿德福韦酯抗病毒治疗过程中持续低病毒载量者耐药突变分析. 中华肝脏病杂志, 2019, 27(10):802-805.
[17] Pal S, Nandi M, Dey D, et al. Myeloid‐derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy. Aliment Pharmacol Ther, 2019, 49(10):1346-1359.
[18] Tseng C, Wu S, Chen C, et al. Characteristics of regulatory T‐cell function in patients with chronic hepatitis B and C coinfection. J Viral Hepat, 2020, 27(8):800-809.
[19] 姜莹, 张碧丽, 王文红. 原发性肾病综合征患儿尿液肾损伤标志物检测的临床意义. 中华实用儿科临床杂志, 2019, 34(17):1326-1330.
[20] 陈慧, 华文进. 视黄醇结合蛋白和脂联素与老年糖尿病肾病患者肾损伤的关系. 中华老年医学杂志, 2019, 38(8):861-863.

阿德福韦酯分别联合恩替卡韦或替诺福韦治疗rtA181V/T单位点突变的慢性乙型肝炎患者疗效初步研究^*

Rescued therapy of patients with chronic hepatitis B and rtA181V/T mutation by adefovir dipivoxiland entecavir or tenofovir combination

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黄俊榕, 吴昌儒, 吴健林. 恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎患者效果研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 327-330.
[2]	罗珂, 丁莉, 刘美. 慢性乙型肝炎患者血清miR-21和miR-148b水平变化及其预测肝组织炎症分级和纤维化分期价值探讨^*[J]. 实用肝脏病杂志, 2022, 25(3): 335-338.
[3]	王广丽, 徐欢, 董丹丹, 黄荷. 慢性乙型肝炎患者血清HBV恩替卡韦耐药基因突变模式调查^*[J]. 实用肝脏病杂志, 2022, 25(3): 339-342.
[4]	严兆兰, 祖红梅, 蔡长霞, 魏巍. 血清低水平丙氨酸氨基转移酶的HBV感染者临床特征分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 343-346.
[5]	李春花, 李忠新, 张春雷, 曾学辉, 陈甜甜, 宋林立. 不同肝纤维化程度的慢性乙型肝炎患者血清FGF-21、PDGF-BB和FBRS水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(3): 347-350.
[6]	姜悦萌, 马于琪, 阚春明, 尹华发. 应用核苷(酸)类治疗慢性乙型肝炎患者早期肾功能的变化^*[J]. 实用肝脏病杂志, 2022, 25(3): 351-354.
[7]	杨艳, 刘婷, 戴琳, 努丽曼姑·麦麦提, 刘环. 声触诊弹性成像检测肝脾硬度诊断慢性乙型肝炎患者肝纤维化效能分析^*[J]. 实用肝脏病杂志, 2022, 25(2): 183-186.
[8]	黄平, 曾霞, 张亚萍, 毛加丽. 肝静脉波形分型联合肝脏超声半定量评分对慢性乙型肝炎患者肝纤维化程度评估价值研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 187-190.
[9]	李振, 宁姗姗, 郭影, 王甜甜, 李莉华, 叶美红, 宋源源. 慢性乙型肝炎患者肝组织LXRα和CYP7A1基因水平变化及其与肝组织炎症和纤维化程度的关系研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 191-194.
[10]	郝玉婷, 林洁, 秦杰. 长期接受恩替卡韦治疗的乙型肝炎肝硬化患者血清水通道蛋白8和水通道蛋白9变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(2): 243-246.
[11]	许政衡, 黄勇, 柯海霞, 李南, 马乙云. 慢性乙型肝炎患者外周血单个核细胞Galectin-3基因水平对聚乙二醇干扰素α治疗应答的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 811-814.
[12]	季旻游, 李超, 赵兴忠, 武煦峰. 恩替卡韦联合复方甘草酸苷治疗乙型肝炎肝硬化患者疗效及对肠道菌群的影响^*[J]. 实用肝脏病杂志, 2021, 24(5): 641-644.
[13]	王利公, 赵珊, 白凯, 张宁, 张楠. 慢性乙型肝炎患者血清α1酸性糖蛋白、α1-抗胰蛋白酶和触珠蛋白变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(5): 673-676.
[14]	吴凤萍, 鲁瑞, 刘怡欣, 王怡恺, 田燕, 张欣, 贾晓黎, 党双锁. 核苷(酸)类似物序贯联合聚乙二醇干扰素α治疗血清HBsAg低水平的慢性乙型肝炎患者疗效分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 677-680.
[15]	周冰清, 杨汉青, 蒋蓓莉. 替诺福韦与恩替卡韦再治疗对α-干扰素治疗不应答的慢性乙型肝炎患者疗效比较研究^*[J]. 实用肝脏病杂志, 2021, 24(5): 681-684.